Text Size
543 studies found for:    Open Studies | "Ovarian Diseases"

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Ovarian Diseases"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting 89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients
Conditions: Ovarian Neoplasms;   Ovarian Diseases;   Adnexal Diseases;   Pancreatic Neoplasms;   Digestive System Neoplasms;   Digestive System Diseases;   Pancreatic Diseases
Intervention: Drug: 89Zr-MMOT0530A
2 Recruiting Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer
Conditions: Ovarian Diseases;   Ovarian Neoplasms
Interventions: Other: Laboratory Tumor Marker Analysis;   Other: Transvaginal Ultrasound;   Other: Health Status Questionnaire
3 Recruiting Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma
Conditions: Genital Diseases, Female;   Ovarian Diseases;   Ovarian Neoplasms;   Endometrial Neoplasms
Intervention: Drug: Temsirolimus
4 Recruiting Evaluation of Optimal Initial Treatment Duration of Bevacizumab in Combination With Standard Chemotherapy in Patients With Ovarian Cancer
Conditions: Genital Diseases, Female;   Ovarian Diseases;   Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms
Interventions: Biological: Bevacizumab;   Drug: Paclitaxel;   Drug: Carboplatin;   Other: specialized pathology review (Germany only)
5 Not yet recruiting Daily Low Dose Chemotherapy and BIBF 1120 in Advanced Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer
Intervention: Drug: BIBF 1120
6 Recruiting Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers
Conditions: Ovarian Cancer;   Endometrial Cancer;   Uterine Cervical Cancer
Interventions: Drug: Filgrastim;   Drug: Paclitaxel;   Drug: Carboplatin
7 Unknown † Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome
Condition: Polycystic Ovary Syndrome
Interventions: Drug: clomiphene citrate;   Drug: raloxifene
8 Recruiting Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: intravenous docetaxel with intraperitoneal oxaliplatin;   Drug: intravenous oxaliplatin with intraperitoneal docetaxel
9 Recruiting Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer
Condition: Adenocarcinoma of the Ovary
Intervention: Biological: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine
10 Recruiting Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity
Conditions: Ovarian Cancer;   Peritoneal Cavity Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study;   Other: laboratory biomarker analysis
11 Recruiting A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma
Conditions: Ovarian Carcinoma;   Relapse
Interventions: Drug: Oxaliplatin;   Drug: oxaliplatin
12 Recruiting Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT
Conditions: Unexplained Infertility;   Polycystic Ovarian Syndrome;   Ovulatory Dysfunction (Absence of or Irregular Ovulation With Unknown Cause)
Interventions: Drug: clomiphene citrate;   Drug: Placebo;   Drug: Nimodipine
13 Recruiting Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer
Condition: Ovarian Cancer
Intervention:
14 Recruiting Benefit of Follicular Flushing During Oocyte Retrieval for Poor Responder Patient in an Assisted Reproductive Technology Program
Conditions: Infertility, Female;   Ovarian Insufficiency
Intervention: Procedure: Direct aspiration needle Echo tip® Cook® single Lumen and Follicular flushing with double lumen needle Echo tip® Cook® Double Lumen Aspiration
15 Recruiting Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer
Conditions: Stage III Ovarian Epithelial Cancer;   Stage III Ovarian Germ Cell Tumor;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor
Interventions: Biological: pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine;   Other: laboratory biomarker analysis
16 Recruiting Psychosexual Intervention in Patients With Stage I-III Gynecologic Cancer
Conditions: Leydig Cell Tumor;   Ovarian Sarcoma;   Ovarian Stromal Cancer;   Stage I Gestational Trophoblastic Tumor;   Stage I Uterine Sarcoma;   Stage I Vaginal Cancer;   Stage I Vulvar Cancer;   Stage IA Cervical Cancer;   Stage IA Endometrial Carcinoma;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IA Primary Peritoneal Cavity Cancer;   Stage IB Cervical Cancer;   Stage IB Endometrial Carcinoma;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IB Primary Peritoneal Cavity Cancer;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage IC Primary Peritoneal Cavity Cancer;   Stage II Endometrial Carcinoma;   Stage II Gestational Trophoblastic Tumor;   Stage II Uterine Sarcoma;   Stage II Vaginal Cancer;   Stage II Vulvar Cancer;   Stage IIA Cervical Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Cervical Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage III Gestational Trophoblastic Tumor;   Stage III Uterine Sarcoma;   Stage III Vaginal Cancer;   Stage III Vulvar Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Endometrial Carcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Cervical Cancer;   Stage IIIB Endometrial Carcinoma;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Endometrial Carcinoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Primary Peritoneal Cavity Cancer
Interventions: Other: questionnaire administration;   Procedure: quality-of-life assessment;   Other: behavioral, psychological or informational intervention
17 Recruiting Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Cognitive/Functional Effects;   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer;   Weight Changes
Interventions: Behavioral: behavioral dietary intervention;   Behavioral: compliance monitoring;   Behavioral: exercise intervention;   Behavioral: telephone-based intervention;   Other: counseling intervention;   Other: educational intervention;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: quality-of-life assessment
18 Unknown † A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse
Condition: Ovarian Cancer Recurrent
Intervention: Drug: Lenalidomide
19 Recruiting A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Carboplatin & paclitaxel;   Biological: Carboplatin & paclitaxel & oregovomab
20 Recruiting Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: VS-6063;   Drug: Paclitaxel
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years